Type II transmembrane serine proteases in cancer and viral infections

Trends in Molecular Medicine

Volumn 15, Issue 7, 2009, Pages 303-312

  Choi, So Young ^a   Bertram, Stephanie ^b   Glowacka, Ilona ^b   Park, Young Woo ^a   Pöhlmann, Stefan ^b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; MATRIPTASE; MEMBRANE PROTEIN; MESSENGER RNA; SERINE PROTEINASE; SIALIDASE; TRANSMEMBRANE SERINE PROTEASE TYPE II; UNCLASSIFIED DRUG;

CARCINOGENESIS; DEREGULATION; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; INFLUENZA VIRUS; MEMBRANE POTENTIAL; NEOPLASM; PARAMYXOVIRUS; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; VIRUS INFECTION;

ANIMALS; CELL MEMBRANE; HUMANS; NEOPLASMS; SERINE ENDOPEPTIDASES; VIRUS DISEASES;

EID: 67650079412     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.05.003     Document Type: Review

References (82)

1. Szabo R., et al. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J. Biol. Chem. 283 (2008) 29495-29504
2. Uhland K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci. 63 (2006) 2968-2978
3. Cheng H., et al. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 69 (2009) 1828-1835
4. Jung H., et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene 27 (2008) 2635-2647
5. List K., et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 19 (2005) 1934-1950
6. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
7. Tomlins S.A., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
8. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15 (2008) 690-698
9. Böttcher E., et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80 (2006) 9896-9898
10. Chaipan C., et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 83 (2009) 3200-3211
11. Wang W., et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods 153 (2008) 111-119
12. Shirogane Y., et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82 (2008) 8942-8946
13. Szabo R., and Bugge T.H. Type II transmembrane serine proteases in development and disease. Int. J. Biochem. Cell Biol. 40 (2008) 1297-1316
14. Hooper J.D., et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276 (2001) 857-860
15. Szabo R., et al. Type II transmembrane serine proteases. Thromb. Haemost. 90 (2003) 185-193
16. Netzel-Arnett S., et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22 (2003) 237-258
17. Scott H.S., et al. Insertion of β-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat. Genet. 27 (2001) 59-63
18. List K., et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21 (2002) 3765-3779
19. Du X., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 320 (2008) 1088-1092
20. List K. Matriptase: a culprit in cancer?. Future Oncol. 5 (2009) 97-104
21. Jin J.S., et al. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod. Pathol. 19 (2006) 447-452
22. Tanimoto H., et al. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br. J. Cancer 92 (2005) 278-283
23. Kobel M., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5 (2008) e232
24. Tsai W.C., et al. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis. Markers 24 (2008) 89-99
25. Jin X., et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 97 (2006) 1327-1334
26. Takeuchi T., et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275 (2000) 26333-26342
27. Bocheva, G. et al. (2009) Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer. J Invest Dermatol. (in press)
28. Oberst M.D., et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8 (2002) 1101-1107
29. Choi S.Y., et al. Role of TMPRSS4 during cancer progression. Drug News Perspect. 21 (2008) 417-423
30. Kebebew E., et al. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg. 242 (2005) 353-361
31. Lin B., et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59 (1999) 4180-4184
32. Vaarala M.H., et al. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 94 (2001) 705-710
33. Sawasaki T., et al. The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer. Tumour Biol. 25 (2004) 141-148
34. Kumar-Sinha C., et al. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8 (2008) 497-511
35. Klezovitch O., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2105-2110
36. Carver B.S., et al. ETS rearrangements and prostate cancer initiation. Nature 457 (2009) E1-E3
37. Lang J.C., and Schuller D.E. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br. J. Cancer 84 (2001) 237-243
38. Sedghizadeh P.P., et al. Expression of the serine protease DESC1 correlates directly with normal keratinocyte differentiation and inversely with head and neck squamous cell carcinoma progression. Head Neck 28 (2006) 432-440
39. Viloria C.G., et al. Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin. Br. J. Cancer 97 (2007) 201-209
40. Lee S.L., et al. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275 (2000) 36720-36725
41. Benaud C., et al. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J. Biol. Chem. 277 (2002) 10539-10546
42. Oberst M.D., et al. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J. Biol. Chem. 278 (2003) 26773-26779
43. Marsh M., and Helenius A. Virus entry: open sesame. Cell 124 (2006) 729-740
44. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3 (2005) 591-600
45. Dushoff J., et al. Mortality due to influenza in the United States-an annualized regression approach using multiple-cause mortality data. Am. J. Epidemiol. 163 (2006) 181-187
46. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69 (2000) 531-569
47. Chu V.C., and Whittaker G.R. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 18153-18158
48. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258 (1999) 1-20
49. Parrish C.R., and Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu. Rev. Microbiol. 59 (2005) 553-586
50. Remacle A.G., et al. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J. Biol. Chem. 283 (2008) 20897-20906
51. Fujimoto S., et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 352 (1998) 873-875
52. Maricich S.M., et al. Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston. Texas. Pediatrics 114 (2004) e626-e633
53. Murakami M., et al. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur. J. Biochem. 268 (2001) 2847-2855
54. Kido H., et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J. Biol. Chem. 267 (1992) 13573-13579
55. Kido H., et al. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr. Pharm. Des. 13 (2007) 405-414
56. Zhirnov O.P., et al. Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J. Virol. 76 (2002) 8682-8689
57. Boycott R., et al. Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology 203 (1994) 313-319
58. Kido, H. et al. (2009) Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. (3 edn) pp. 167-175
59. Jacquinet E., et al. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur. J. Biochem. 268 (2001) 2687-2699
60. Lucas J.M., et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J. Pathol. 215 (2008) 118-125
61. Garten, W. et al. (2004) Cleavage of influenza virus hemagglutinin by host cell proteases (1263 edn) pp. 218-221
62. Donaldson S.H., et al. Regulation of the epithelial sodium channel by serine proteases in human airways. J. Biol. Chem. 277 (2002) 8338-8345
63. Kim T.S., et al. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol. Cell. Biol. 26 (2006) 965-975
64. Takahashi M., et al. Localization of human airway trypsin-like protease in the airway: an immunohistochemical study. Histochem. Cell Biol. 115 (2001) 181-187
65. Yamaoka K., et al. Cloning and characterization of the cDNA for human airway trypsin-like protease. J. Biol. Chem. 273 (1998) 11895-11901
66. Yasuoka S., et al. Purification, characterization, and localization of a novel trypsin-like protease found in the human airway. Am. J. Respir. Cell Mol. Biol. 16 (1997) 300-308
67. Chokki M., et al. Human airway trypsin-like protease induces amphiregulin release through a mechanism involving protease-activated receptor-2-mediated ERK activation and TNF α-converting enzyme activity in airway epithelial cells. FEBS J. 272 (2005) 6387-6399
68. Miki M., et al. Effect of human airway trypsin-like protease on intracellular free Ca2+ concentration in human bronchial epithelial cells. J. Med. Invest. 50 (2003) 95-107
69. Beaufort N., et al. The human airway trypsin-like protease modulates the urokinase receptor (Upar, CD87) structure and functions. Am. J. Physiol. Lung Cell. Mol. Physiol. 292 (2007) L1263-L1272
70. Wallrapp C., et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60 (2000) 2602-2606
71. Garcia-Caballero A., et al. ENaC proteolytic regulation by channel-activating protease 2. J. Gen. Physiol. 132 (2008) 521-535
72. Kido H., and Okumura Y. MSPL/TMPRSS13. Front. Biosci 13 (2008) 754-758
73. Kim D.R., et al. Cloning and expression of novel mosaic serine proteases with and without a transmembrane domain from human lung. Biochim. Biophys. Acta 1518 (2001) 204-209
74. Tumpey T.M., et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310 (2005) 77-80
75. Rimmelzwaan G.F., et al. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am. J. Pathol. 168 (2006) 176-183
76. Gambotto A., et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371 (2008) 1464-1475
77. Steinmetzer T., et al. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J. Med. Chem. 49 (2006) 4116-4126
78. Desilets A., et al. Inhibition of human matriptase by eglin c variants. FEBS Lett. 580 (2006) 2227-2232
79. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
80. Chevillet J.R., et al. Identification and characterization of small-molecule inhibitors of hepsin. Mol. Cancer Ther. 7 (2008) 3343-3351
81. Taubenberger J.K. The origin and virulence of the 1918 "Spanish" influenza virus. Proc. Am. Philos. Soc. 150 (2006) 86-112
82. Ahmed R., et al. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 8 (2007) 1188-1193